Alector Prices 36.6 Million Share Stock Offering
The South San Francisco-based biotech company expects to generate $75 million in gross proceeds from the stock sale.
Updated on Oct. 16, 2026 in Alzheimer’s
Live Poll
Is now a good time for individual investors to buy into new biotechnology stock offerings?
Alector has priced an underwritten offering of 36,600,000 shares of common stock at $2.05 per share. This price marks a 7.3% premium over the company's closing price from October 15, 2026.
Why it matters
The capital raised will fund ongoing research, development, and manufacturing efforts for the company's pipeline. These proceeds are also earmarked for working capital and potential future acquisitions.
Alector is offering 36,600,000 shares of common stock at a price of $2.05 per share, resulting in anticipated gross proceeds of $75,030,000. This offer reflects a 7.3% premium over the closing price recorded on October 15, 2026.
The players
Alector
Alector is a South San Francisco-based biotechnology company focused on developing immunotherapies for neurodegenerative diseases.
Morgan Stanley
Morgan Stanley is a multinational investment bank and financial services company that served as a joint lead book-running manager.
BTIG
BTIG is a global financial services firm specializing in institutional trading and investment banking services.
The details
The offering is being managed by Morgan Stanley and BTIG as joint lead book-running managers. Several investment firms, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, are participating in the purchase.
Timeline
October 15, 2026: The closing price used to calculate the 7.3% premium.
October 16, 2026: The official pricing of the underwritten stock offering.
October 19, 2026: The expected closing date for the share offering.
The Big Picture
The stock offering follows the regulatory framework established by the SEC's shelf registration statement. This mechanism allows biotech firms to raise capital efficiently by pre-registering securities for future sale when market conditions are favorable.
While this financial move does not change immediate treatment access, it secures the long-term funding necessary for ongoing clinical research. Investors and patients should monitor future trial updates as the company deploys these newly raised funds.
The takeaway
Companies in the biotech sector frequently use follow-on offerings to sustain high-cost research and development cycles. Investors should track how effectively these proceeds translate into future milestones in drug candidate pipelines.
What happens next
The offering is expected to close on or about October 19, 2026.
Further reading
For broader context on developments in the neurodegeneration sector, visit the Alzheimer’s section.
More information
Review the full details of the financial filing on the SEC website for prospectus.
Live Poll
Is now a good time for individual investors to buy into new biotechnology stock offerings?
